Drug Treatment Hiv
Drug Treatment Hiv
HIV Market has Strong Competition Between Several Marketed and Combination Products
HIV AIDS – Drug Pipeline Analysis and Market Forecasts to 2016
This report provides the key data, information and analysis on the HIV/AIDS market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecast seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with HIV/AIDS, competitive assessment, the product profiles of the major marketed products and the promising drugs in the pipeline, an overview of the discontinued projects, the implications for future market competition, and the key players in the HIV/AIDS market. ( http://www.bharatbook.com/detail.asp?id=134479&rt=HIV-AIDS-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html )
The HIV/AIDS Therapeutics Market is Forecast to Show Moderate Growth To 2016
This analysis suggests that the global Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) market was worth $12 billion in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2% for the next seven years to reach $13.7 billion by 2016. The global HIV infection market will continue to grow between 2009 and 2016 at a moderate rate due to a series of patent expiries in this period. The growth rate is likely to decline from 2012 onwards due to the impact of patent expiries of key drugs. However, migration to new branded drugs is likely to minimize the impact of generics. This moderate growth will be driven by an increasing prescription rate and increased usage of newer drugs such as Atripla as part of Highly Active Antiretroviral Therapy (HAART).The number of people taking treatment for HIV is increasing and the average annual cost of therapy for Antiretroviral Treatment (ART) is forecast to increase at a higher rate over the next two years with an expected price decline from 2012 onwards due to a series of patent expirations. The market is characterized by a high unmet need of drugs in terms of efficacy and drugs which can cure the disease. HAART requires patients to take different classes of drugs and has succeeded in achieving near zero levels of HIV in infected people however. The increased uptake of HAART and increasing awareness will drive the market. Therefore despite challenges such as the lack of a cure and the risk of building drug resistance to current marketed drugs, the HIV market will continue to grow at a moderate rate.
The HIV Market has Strong Competition Between Several Marketed and Combination Products
It analyzed the current competitive landscape for HIV/AIDS drugs and found the competition to be strong. There are more than 30 marketed products from different classes of therapies for the treatment of HIV. However, all these classes of drugs are relatively high on safety but moderate on efficacy. This is because there is no cure for the infection on the market. In addition, some of the new multi-class combination drugs have improved the efficacy in terms of lowering HIV levels in the body. Therefore drugs compete on efficacy in terms of delaying the progression of the disease and combination drugs are considered far better in this regard. The drugs on the market today aim to prolong the time it takes for the HIV infection to become AIDS. This has led to an increase in the average life expectancy of people infected with HIV. Overall, the HIV/AIDS market is in need of products with better efficacy profiles and those which promise to cure the disease.
The Unmet Need of a Cost Effective Cure is Unlikely to be Fulfilled in the Coming Years
It has found that the global HIV/AIDS market is a highly lucrative market with high levels of unmet need in terms of drug efficacy and curing the disease. The HIV market consists of a large number of drugs that are approved for HIV but none that can cure the disease. All these drugs need long term usage and the length of the therapy can last approximately 20 years. The HIV drugs on the market are considered safe as the side effects associated with HIV drugs are minimal when compared with the effects of the untreated progression of the disease itself. The disease can be fatal and is associated with many opportunistic infections which decrease the quality of life of the infected person. Therefore, while the unmet need for the HIV market will remain, some newer drugs may offer better treatment for drug-resistance HIV or have better efficacy in terms of lower dosage frequencies to improve patient compliance and improve treatment quality in the coming years.
Strong Clinical Pipeline with Several First-in-Class Molecules
It analyzed the HIV/AIDS pipeline and found it to be strong. The pipeline for HIV consists of more than 250 molecules currently in development for various disease segments. There are many companies active in developing HIV drugs. In addition to the leading market players, Boehring Ingelheim, Achillion Pharmaceuticals, GlaxoSmithKline, Incyte and Pharmasset, Shire Pharmaceuticals and Tibotec Virco are active in developing drugs for the HIV therapeutics market. The pipeline for HIV/AIDS is strong as many pharmaceutical companies today are primarily focusing on the new antiviral agents which offer effective treatment options for patients who no longer respond to existing therapies. As a result, the treatment paradigm for HIV has evolved from monotherapy to triple combination treatment known as HAART. The HIV/AIDS clinical pipeline is strong with several first-in-class molecules in development. Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and protease inhibitors are most popular drug classes in which most pipeline activity is currently taking place. Overall, there are 101 first-in-class molecules which accounts for 41% of the pipeline. Multi-class combination therapies and me-too products account for approximately 42% of the clinical pipeline and are expected to improve on the safety profiles of marketed drugs.
To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=134479&rt=HIV-AIDS-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
Or
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com
Follow us on twitter: http://twitter.com/3bbharatbook
About the Author
We are the leading information aggregator, facilitates and supports the business information needs. With over 115,000 reports, you can get instant access and insights on the studies in yo for market research , corporate / strategic planning by providing the latest information in the form of reports, journals, magazines and databases on varied industries like automotive, oil and gas, shipping, textiles, pharmaceuticals, energy, banking, finance, insurance, risk management, country intelligence, consumer & durable goods, chemical and more ur areas of interest. Contact us at +91 22 27578668 / 27579438 or email info@bharatbook.com or our website www.bharatbook.com
HIV/AIDS Research?
what types of technology do drug companies use in the development of HIV treatments?
Its part of a Science project… can anyone help?
Check out Glaxo Smith Klines website. As well as universities such as Kansas University. The Mayo clinics website might be able to help you as well.
HIV Abdominal Obesity & Insulin Resistance: Treatment with IGF-1/IGFBP-3
|
|
Drug Rehabilitation (How to Choose a good drug rehab) This is not a book about drugs, or the inevitable consequences of drug use. There are plenty of books about that already.It is about taking a close hard look at the Drug Rehabilitation programs available to people who need them, and the importance of truly studying and assessing these programs. It is hard to get a clear perspective when the varieties of treatment options to lead a healthy, drug-fr… |
|
|
Love Me: A look into a life of abuse, sex, drugs, and bipolar disorder $12.64 Kassi Visage-Lowe was born Kassi Lee Schlangen in Spokane, Washington, January 9, 1959. She was happy, excited about life, a little girl with promise for the future. She was talented, loved to sing and draw and express herself. She found that school was easy for her. Social contacts were not. Kassi would speak up when challenged and fight you when wronged. She became combative and defensive-she m… |
|
|
12 Smart Things to Do When the Booze and Drugs Are Gone: Choosing Emotional Sobriety through Self-Awareness and Right Action $8.82 Whether it’s called ‘dry drunk’ or ‘white knuckle sobriety,’ it’s that stage in recovery when we realize that ‘putting the plug in the jug’ isn’t enough. The next step is taking responsibility for the emotional immaturity that fuels our addictive personality and has a tremendous impact on ourselves and others.In 12 Smart Things to Do When the Booze and Drugs Are Gone, Allen Berger, Ph.D., draws on… |
|
|
ABC News Primetime Family Secrets: Inside Addiction $19.95 … |
|
|
May Day $1.99 … |
|
|
Up On the Roof $1.99 … |
|
|
Schonberg Rehab is for Quitters Distressed Retro Vintage Tin Sign $9.95 Schonberg Rehab is for Quitters Distressed Retro Vintage Tin Sign… |
|
|
Schonberg Rehab is for Quitters Distressed Retro Vintage Tin Sign $9.99 Schonberg Rehab is for Quitters Distressed Retro Vintage Tin Sign… |
|
|
Schonberg Rehab is for Quitters Distressed Retro Vintage Tin Sign $12.99 Schonberg Rehab is for Quitters Distressed Retro Vintage Tin Sign… |
|
|
Network Therapy for Alcohol and Drug Abuse: Effective Office-Based Treatment [VHS] $39.97 Treatment of substance abuse is challenging for all involvedAfor addicted patients, those close to them, and the treating therapists. This informative video shows how a therapist complements individual sessions with supportive meetings with the patient, family, and friends to surmount major obstacles to recovery. The video portrays reenacted therapy sessions using transcripts from actual sessions … |
